


August 29, 2006



uOttawa

Institute of Mental Health Research

at the Royal Ottawa Health Care Group

Research Report 2005

"Fostering integrated research...from the neuron to the neighbourhood"




Table of Contents

Mission, Vision, Values.....	3
Board of Directors.....	4
Report from the President.....	6
Research Units.....	7
Overview of Research Activities.....	14
Grants and Contracts 2005.....	15
Papers Published in Peer-Reviewed Journals.....	27
Other Publications.....	33
Invited Lectures, Participation in Public Forums.....	38
Media Presentations.....	44
Public Lectures and Invited Addresses.....	46
IMHR Educational Events: 2005.....	51
Appendix 1 Scientific Advisory Board Members.....	54

Mission, Vision, Values


Mission

Create scientific knowledge to improve mental health and well-being locally and globally.



Vision

To be a premier research institute with national and international centre of excellence status that continuously improves mental health and well-being through leadership, collaborative discoveries and innovation in research, patient care and education.



Values

The core values of the IMHR are excellence, collaboration, integrity, respect, compassion, wellness and equity.



Board of Directors

Murray J. Elston (Chair) is President and CEO of the Canadian Nuclear Association (CNA), a non-profit organization established in 1960 to represent Canada's nuclear industry and promote the development and growth of nuclear technologies for peaceful purposes. Mr. Elston provides leadership and guidance to strategically position the IMHR as a Centre of Excellence in mental health research.



Myrna Barwin (Vice-Chair), Co-Founder, President and COO of Zequra Technologies

Roxanne L. Anderson, Partner with Pricewaterhouse-Coopers LLP in Ottawa

Scott Anderson, Editor of The Ottawa Citizen

Dr. Caroline Andrew, Dean of the Faculty of Social Sciences at the University of Ottawa

Elizabeth (Lisa) Cogan, Head of the Jewish National Fund

Dr. Pierre Blier, Professor of Psychiatry at the University of Ottawa, Endowed Chair in Mood Disorders Research at the IMHR, Canada Research Chair in Psychopharmacology

Dr. Jacques Bradwejn, Chief of Psychiatry at the Royal Ottawa Hospital and Chair of the Department of Psychiatry at the University of Ottawa

Wendy L. Cohen, Director of Chartwell Communications Consultants Inc.

Scott M. Eaton, Corporate and securities lawyer

Dr. Henry P. Edwards, Director of the Research and Development Division, Personnel Psychology Centre, Public Service Commission of Canada

Dr. Martine F. Flament, Director of the Youth Research Unit, Professor in the Department of Psychiatry at the University of Ottawa

Brian J. Ford, Former Chief of Police of the Ottawa-Carleton Regional Police Service

Dr. Robert Haché, Vice Dean, Research, for the Faculty of Medicine at the University of Ottawa

Timothy J. Kluge, President and CEO of the Royal Ottawa Health Care Foundation

Patrick D. Lafferty, Retired partner, with more than 38 years with PricewaterhouseCoopers LLP.

Dr. Zul Merali, President and CEO of the University of Ottawa Institute of Mental Health Research, Professor in the faculties of Medicine & Social Science at the University of Ottawa

Dr. John R. Rutherford, Retired executive with more than 30 years of experience in the private, public and academic sectors

August 29, 2006

Board of Directors

Bruce H. Swan, President and CEO of the Royal Ottawa Health Care Group

Shirley Westeinde, Chair of the Westeinde Group of Companies. Specializing in Development, Property Management, Leasing and Green Building Design and Development.

Report from the President



It gives me great pleasure to mark the end of yet another successful year of research at uOttawa Institute of Mental Health Research (IMHR). This report highlights a small sample of the many activities that exemplify excellence in research at the IMHR in 2005. Our researchers garnered over \$3.6 million in grants and contracts. At the IMHR research is not just about creating new scientific knowledge – it is also about translating these discoveries into improved clinical care, locally and globally. Indeed, our researchers served as teachers and mentors for over 25 graduate students, and post-doctoral fellows; and their work resulted in over 65 peer-reviewed scientific papers in 2005 alone. Their work was also featured in scores of newspaper, radio and television stories, bringing hope and inspiration for a better tomorrow. We all applaud the scientists, clinical and research staff, students, post-doctoral fellows and volunteers for their dedication and outstanding work.

The soon to open new Royal Ottawa Hospital campus, includes a prominent research tower, the new home of the IMHR. This state-of-the-art research facility includes “Dry Labs” (Clinical Research Space), “Wet Labs” (for bench top molecular and genetic research), as well as educational and administrative infrastructure. In the future, it will also house a Brain Imaging Centre and a vivarium. This facility will bring together researchers who can investigate all aspects of mental disorders, from the molecule to the cell, and from the patient’s bedside to the community. Our vision is a centre of excellence where the free exchange of ideas, knowledge and skills can open new frontiers in the understanding, treatment and prevention of mental illness - promoting research from the neuron to the neighbourhood.

Zul Merali, Ph.D.
President & Chief Executive Officer
uOttawa Institute of Mental Health Research
Royal Ottawa Hospital

Research Units

Forensic Research Unit

Dr. Paul Fedoroff and the Forensic Research Unit

In 2005, the Sexual Behaviors Clinic of the Royal Ottawa Hospital and the IMHR Forensic Research Unit, directed by Dr. Paul Fedoroff, hosted the annual meeting of the International Academy of Sex Research which brought the leading sex researchers in the World to Ottawa for the first time. Since then, the Unit has hosted clinicians and researchers from Japan, the United Kingdom, the United States and South America who have sought assistance in emulating the success of this unit and the internationally renowned Integrated Forensic Program. One reason for this success is the commitment of the program to excellence in clinical care, teaching and innovative research. Of particular note is the program's interest in vulnerable populations that have previously gone largely unnoticed. One of these consists of men and women with intellectual disability.

In a recent study partially funded by the CIHR, the IMHR Forensic Research Unit discovered that standard assessment tools used to assess the risk of re-offense in men with histories of sex crimes may not be applicable in men with developmental delay. The reason is that items associated with risk in men with normal intelligence may have different significance in men with intellectual disabilities.

People often imagine that a clinical program focused on the assessment and treatment of people accused of sexual offenses is one of despair. In truth the Sexual Behaviors Clinic of the Royal Ottawa Health Care Group frequently deals with men who themselves are victims with severe psychiatric and intellectual impairments. While this in no way diminishes the harm they have caused, research projects like the ones carried out here hold the promise of a future in which men and women who might commit sex offenses can be identified and treated before others are harmed. In part due to innovative assessment and treatment, the incidence of sex crimes is dropping and the re-offense rate of sex offenders is now less than 15%. Planned research aims to drop this rate even further.

Research Units

Mood Disorders Research Unit

Dr. Pierre Blier and the Mood Disorders Research Unit

The mission of the Mood Disorders Research Unit is to improve the remission rate of depressed patients and to get them well faster. This research group is unique in Canada as it encompasses fully integrated fundamental and clinical research units. Directed by Pierre Blier, M.D., Ph.D., a clinician scientist, this model represents the best strategy to bridge the laboratory bench to the patient's bedside, thereby providing an ideal environment to facilitate translational research.

The clinical research unit is responsible for devising research studies aimed at assessing the biochemical and clinical effects of various antidepressants and new molecules in development. The most recent studies were aimed at accelerating and improving the antidepressant response by using combinations of two medications from treatment initiation in comparison to giving only one medication; a technique often employed in other areas of medicine. These combinations, while being very well tolerated, have more than doubled the usual remission rate of standard medications within a six week treatment period, thereby saving time, and attenuating the burden and suffering of patients and families. Finally, the unit offers a consultation service for treatment-resistant patients that integrates an on-going project examining the relationships between brain morphology and genetic factors that may be relevant to the development and treatment of depression. Drs. Bisserbe and Habib are staff psychiatrists working in this research unit, as well as post-doctoral fellows. Ms. Chantal Hébert is the research nurse coordinator in charge of the clinical projects.

This program is supported by peer-reviewed grants from provincial and federal agencies, as well as from investigator-initiated studies sponsored by the pharmaceutical industry. Dr. Blier holds the Canada Research Chair in Psychopharmacology from the Government of Canada.

Research Units

Schizophrenia Research Unit

Dr. Patrice Boyer and the Schizophrenia Research Unit

The Schizophrenia Research Unit of the uOttawa Institute of Mental Health Research was formed in 2004 under the leadership of Dr. Patrice Boyer, who was recruited from the University of Paris 6 Pitié-Salpêtrière. It is supported by a diverse array of sources including the Royal Ottawa Health Care Foundation, the Canada Foundation for Innovation, the Ministry of Economic Development and Trade, and the France-Canada Research Foundation.

Dr. Boyer's lab is currently investigating the relationships among long-term memory deficits, hippocampal dysfunction, and functional outcome in schizophrenia patients. Probing neural activity in the hippocampus is possible with virtual reality technology and functional magnetic resonance imaging (fMRI). fMRI and morphological data analyses will be conducted under the supervision of the McConnell Brain Imaging Centre at McGill University, Montreal.

For example, since patients may not have the ability to store memories bound with their appropriate context, contextual cues in the environment make little sense, and memories cannot be counted upon to provide cues for appropriate behaviour. Perhaps most importantly, memories cannot be used to form an intact autobiographical memory of life events and their contexts, e.g., "what happened, where did it happen, with whom did it happen, and when did it happen?" The impact of this deficit in a patient's daily life and on their abilities to "test reality" is extremely important and can explain a great deal of the symptoms they are presenting.

Research Units

Stress and Anxiety Clinical Research Unit

Dr. Diana Koszycki and the Stress and Anxiety Clinical Research Unit

Founded in 1998 by Drs. Diana Koszycki and Jacques Bradwejn, the Stress and Anxiety Clinical Research Unit (SACRU) focuses on research on the etiology and treatment of anxiety disorders. Members of SACRU have made significant contributions to understanding the nature and treatment of anxiety disorders. Current research in SACRU includes, identifying protective and risk factors in children at genetic risk for panic disorder, genetic studies in panic disorder, evaluating genetic mediators of panic disorder sensitivity to cholecystokinin (CCK), pharmacological treatment studies in generalized anxiety disorder and treatment refractory panic disorder, evaluating alternative and innovative psychological interventions for social anxiety disorder (mindfulness meditation) and generalized anxiety disorder (spiritually-based cognitive therapy); and evaluating the efficacy of medication and psychotherapy in depressed cardiac patients. These studies are funded by peer-reviewed grants from federal and provincial agencies, from the University Medical Research Funds, and from industry. Members of the unit, Dr. Jakob Shlik (Clinical Director, Anxiety Disorders Program), Dr. Jacques Bradwejn (Chair, Department of Psychiatry), Paula Loja, B.Sc., R.N. (research nurse-co-ordinator) and research assistants Ramona Eryuzulu, M.A., Diana Al Sarakbi, B.A. and Manon Bertrand (Ph.D. candidate).

Recently, Dr. Koszycki, received a grant from the Ontario Mental Health Foundation to evaluate the efficacy of interpersonal psychotherapy (IPT), a first-line depression-focused intervention, in depressed infertile women. In addition to causing significant suffering and impairment, research suggests that depression can impact negatively on infertility and its treatment. Despite these findings, there are few trials and no evidence-based clinical guidelines for managing depression in this subgroup of depressed women. The findings of this study will have important implications for the proper care of depressed women coping with infertility.

Research Units

Youth Research Unit

Dr. Martine Flament and Youth Research Unit

The IMHR Youth Research Unit was initiated in January 2003. The main areas of research are the eating disorders (ED), obsessive-compulsive disorder (OCD), other anxiety disorders, and mood disorders in children and adolescents. The unit aims at identifying the risk and resilience factors involved in the onset and maintenance of these disorders, and investigating the mechanisms of action of effective treatments. Research is community-based (e.g., study of risk and protective factors for eating and weight disorders in high school students) or based on the assessment and treatment of referred patients (e.g., biological and psychological correlates of anxiety disorders in adolescents; effects of anti-obsessional medication on executive functions, metacognition and regional brain activations). Through collaboration with international agencies -- World Psychiatric Association (WPA), World Health Organization (WHO), the French National Institute for Health and Medical Research (INSERM - Institut national de la santé et de la recherche médicale). The unit also investigates and promotes evidence-based treatment and prevention strategies for mental disorders in children and adolescents.

Within the University of Ottawa Department of Psychiatry, the Youth Research Unit has developed working links with the Division of Child and Adolescent Psychiatry, which includes both the ROH Clinical Youth Program and the Psychiatric Services at the Children's Hospital of Eastern Ontario (CHEO). The Youth Research Unit welcomes and tutors graduate and undergraduate students from the University of Ottawa and Carleton Schools of Psychology.

Dr. Flament has recently received funding from a variety of sources including, as principal investigator, the Provincial Centre of Excellence for Child and Youth Mental Health at CHEO, the Ontario Ministry of Research and Innovation, the University Medical Research Fund (UMRF), and, as co-investigator, Canadian Institutes of Health Research (CIHR), with Drs. Matheson and Anisman at Carleton University and Social Sciences and Humanities Research Council of Canada (SSHRC), with Dr. Schneider at the University of Ottawa.

Research Units

Sleep Disorders

Dr. Alan Douglass and the ROHCG Sleep Disorders Clinic

The ROH Sleep Disorders Clinic, directed by Dr. Alan Douglass, is an outpatient clinic where patients with suspected sleep disorders are referred by general practitioners or specialists in other areas. While the Sleep Disorder Clinic can diagnose any sleep disorder in their sleep laboratory (obstructive sleep apnea, narcolepsy, periodic limb movements), they are especially interested in the diagnosis of sleep disorders in psychiatric patients, and psychiatric symptoms in general medical patients.

Because most chronic insomnia is associated with depression, anxiety, or bipolar spectrum disorders, this clinic is better able to treat insomnia relative to other local sleep clinics. Moreover, members of the Sleep Clinic have presented papers on heartbeat irregularities in sleep apnea, chronic insomnia, and the mis-diagnosis of narcolepsy patients as schizophrenic. They have also developed research sleep questionnaires, and sponsor research projects of undergraduate students from the University of Ottawa School of Psychology.

Dr. Douglass is also conducting basic pharmacology research into the control of eye movements (EM's) in Rapid Eye Movement sleep (REM sleep), where most of the night's dreaming occurs. EM's, which are controlled by the neurotransmitter acetylcholine and respond to drugs that block or assist acetylcholine are most pronounced among depressed individuals, when compared to healthy controls. The research involves drugs that probe the acetylcholine system to create tests that predict treatment response in depressed patients, and the risk of depression in their family members.

In the new ROHCG/IMHR facility, the Sleep Clinic will have 5 clinical sleep disorder bedrooms for overnight studies. In addition, they will share space with Neurophysiology/EEG that will provide 3 or 4 more beds for pure research studies. This will considerably expand their research capability and attract more researchers and graduate students.

Research Units


Neuroelectrophysiology Laboratory

Dr. Verner Knott and the Neuroelectrophysiology Laboratory

The Neuroelectrophysiology Laboratory of the ROH and uOttawa Institute of Mental Health Research, led by Dr. Verner Knott is engaged in research exploring brain mechanisms that underly cognitive and affective processes in patients with psychiatric disorders. The probing of these processes is carried out using two cerebral electric tools, digital electroencephalography (EEG) and event-related potentials (ERPs), which allow for precise monitoring of human brain activity associated with spontaneous or induced cognitive or emotional states. Although often employed clinically, their strength in neuroscience research lies in their ability to contribute to the understanding of neural mechanisms underlying disturbances in emotion, mood and information processing.

Currently, this laboratory is concerned with projects examining the relationship between nicotine and mood (depression) and cognitive (schizophrenia) disorders. Funding through federal, provincial, university and industry-sponsored grants supports projects examining both the causative and potentially ameliorative role of nicotine in lowered mood and faulty mental processing in depressed and psychotic patients. These funds also help to support mentoring programs for graduate and undergraduate students from Carleton University and the University of Ottawa.

Overview of Research Activities



2005 saw a stabilization of funding for both industry and peer-reviewed research. In the year 2005 Industry contracts accounted for 24% of the total research funding received.

Grants and Contracts 2005

Funding Source Abbreviations:

CF - Change Foundation
CFI - Canadian Foundation for Innovation
CIHR - Canadian Institutes of Health Research
ROHCF – Royal Ottawa Health Care Foundation
ROHCG - Royal Ottawa Health Care Group
UMRF - University Medical Research Fund
CPRF - Canadian Psychiatric Research Foundation
OIT- Ontario Innovation Trust
OMHF - Ontario Mental Health Foundation
SSHRC – Social Sciences and Humanities Research Council of Canada
NSERC- Natural Sciences and Engineering Research Council of Canada

Grants and Contracts Awarded in 2004: Active in 2005

Project Title: Behavioral and neurochemical responses to acute, subchronic, and chronic intermittent stressors in relation to depression: Moderation by genetic and early life events

PI: Anisman, H.

Co-Investigators: Merali, Z.; Poulter, M.

Funding Agency: CIHR

Funding Amount: \$695,950

Duration: 2004-09

Project Title: Identifying the facilitators and obstacles to overcoming homelessness

PI: Aubry, T.

Co-Investigators: Farrell, S.

Funding Agency: SSHRC

Funding Amount: \$100,000

Duration: 2004-06

Project Title: Treatment-resistant depression and 5HT1A receptor gene polymorphism

PI: Bisserbe, J-C.

Co-Investigators: Kraus, R.; Albert, P.

Funding Agency: UMRF

Funding Amount: \$69,998

Duration: 2004-06

Project Title: Improving the treatment of major depression: The bench to the bedside approach

PI: Blier, P.

Co-Investigators: n/a

Funding Agency: Canada Research Chairs

Funding Amount: \$1,400,000

Duration: 2004-11

Grants and Contracts 2005

Project Title: Elucidation and optimization of the mechanisms of action of antidepressant treatments using electrophysiological recording techniques in animals and application of the results to the clinical setting

PI: Blier, P.

Co-Investigators: n/a

Funding Agency: CFI

Funding Amount: \$124,812

Duration: 2004-05

Project Title: Elucidation and optimization of the mechanisms of action of antidepressant treatments using electrophysiological recording techniques in animals and application of the results to the clinical setting

PI: Blier, P.

Co-Investigators: n/a

Funding Agency: OIT

Funding Amount: \$124,812

Duration: 2004-05

Project Title: Risperidone augmentation of SSRIs in depression: A noradrenergic action?

PI: Blier, P.

Co-Investigators: n/a

Funding Agency: Janssen Pharma

Funding Amount: \$175,500

Duration: 2004-05

Project Title: Effectiveness of the dual serotonin norepinephrine reuptake inhibitor venlafaxine in depressed patients

PI: Blier, P.

Co-Investigators: Bisserbe, J-C.; Kraus, R.

Funding Agency: Wyeth Pharma

Funding Amount: \$540,401

Duration: 2004-05

Project Title: Assessment of augmentation strategies to optimize the therapeutic response to mirtazapine in major depression

PI: Blier, P.

Co-Investigators: Bergeron, R.; Bisserbe, J-C.; Kraus, R.

Funding Agency: Organon Pharma

Funding Amount: \$164,600

Duration: 2004-05

Grants and Contracts 2005

Project Title: Effect of sustained administration of escitalopram on the 5-HT system in heterozygous mice for the 5-HT transporter, SCT-TX-15000

PI: Blier, P.

Co-Investigators: n/a

Funding Agency: Forest Lab, Inc.

Funding Amount: \$166,251

Duration: 2004-05

Project Title: Electrophysiological exploration of the antidepressant potential of Wf-516 on the serotonin and norepinephrine systems

PI: Blier, P.

Co-Investigators: n/a

Funding Agency: Mitsubishi Pharma

Funding Amount: \$81,250

Duration: 2004-05

Project Title: Randomized trial on the efficacy of meditation-based stress reduction program and cognitive behavior therapy in the treatment of generalized social anxiety disorder: A pilot study

PI: Bradwejn, J.

Co-Investigators: Koszycki, D.; Shlik, J.

Funding Agency: UMRF

Funding Amount: \$34,363

Duration: 2004-05

Project Title: REM sleep density and HPA dysregulation in bipolar disorder

PI: Douglass, A.

Co-Investigators: Grof, P.

Funding Agency: UMRF

Funding Amount: \$34,100

Duration: 2004-05

Project Title: The evolution of bipolar disorder in youths at risk: A prospective longitudinal study of the clinical course of illness and associated changes in neurocognitive functioning and gene expression among the offspring of well-characterized bipolar parents

PI: Duffy, A.

Co-Investigators: Kutcher, S.; Grof, P.; MacQueen, G.; Alda, M.; Young, T.

Funding Agency: CIHR

Funding Amount: \$397,816

Duration: 2004-09

Grants and Contracts 2005

Project Title: A longitudinal study of the children of bipolar parents

PI: Duffy, A.

Co-Investigators: Milin, R.

Funding Agency: CIHR

Funding Amount: \$96,605

Duration: 2004-06

Project Title: A prospective study of neurocognitive functioning among adolescents at high risk for bipolar disorder

PI: Duffy, A.

Co-Investigators: Grof, P.; Milin, R.; Alda, M.; MacQueen, G.

Funding Agency: OMHF

Funding Amount: \$74,780

Duration: 2004-06

Project Title: Quetiapine maintenance treatment in early onset bipolar spectrum disorders: An open prospective longitudinal study of the effectiveness of quetiapine monotherapy in preventing relapse and minimizing neurocognitive dysfunction among adolescents manifesting bipolar spectrum disorders

PI: Duffy, A.

Co-Investigators: Milin, R.; Grof, P.

Funding Agency: AstraZeneca

Funding Amount: \$202,937

Duration: 2004-07

Project Title: Validation of risk assessment tools for individuals with problematic sexual behaviour and developmental delay

PI: Fedoroff, P.

Co-Investigators: Curry, S.; Richards, D.; Griffiths, D.; Bradford, J.

Funding Agency: CIHR

Funding Amount: \$100,000

Duration: 2004-05

Project Title: Human rights and health self-advocacy training for people who have intellectual disabilities: A multisystemic, interdisciplinary approach

PI: Feldman, M.

Co-Investigators: Owen, F.; Griffiths, D.; Tardif, C.; Tarulli, D.; McQueen-Fuentes, G.; Sales, C.A.; Fedoroff, P.

Funding Agency: CIHR

Funding Amount: \$305,751

Duration: 2004-07

Grants and Contracts 2005

Project Title: Correlates of eating and weight disorders in a community-based adolescent population: Investigating an integrative biopsychosocial model

PI: Flament, M.

Co-Investigators: Henderson, K.A.; Buchholz, A.; Goldfield, G.

Funding Agency: UMRF

Funding Amount: \$34,777

Duration: 2004-06

Project Title: A multicentre, randomized controlled trial of negative ion generation versus light-emitting diode phototherapy for seasonal affective disorder

PI: Horn, E.

Co-Investigators: Knott, V.; Telner, J.; Moorhouse, M.; Bhatla, R.

Funding Agency: Litebook Co.

Funding Amount: \$83,687

Duration: 2004-05

Project Title: CCK-B receptor polymorphism and vulnerability to CCK-4 induced panic attacks in healthy subject

PI: Koszycki, D.

Co-Investigator: Bradwejn, J

Funding Agency: CIHR

Funding Amount: \$141,364

Duration: 2003-05

Project Title: Children at risk for panic disorder

PI: Koszycki, D.

Co-Investigators: Bradwejn, J.; Flament, M.

Funding Agency: CIHR

Funding Amount: \$214,509

Duration: 2004-07

Project Title: An open-label study of the efficacy and safety of Risperdal long-acting microspheres (Risperdal Consta™) administered once monthly in adults with schizophrenia or schizoaffective disorder (extension phase)

PI: Labelle, A.

Co-Investigators: Bourget, D.; Habib, R.; Tessier, P.

Funding Agency: Janssen-Ortho

Funding Amount: \$52,000

Duration: 2004-06

Grants and Contracts 2005

Project Title: A randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary disease.

PI: Lesperance, F.

Co-Investigators: Frasure Smith, N., Koszycki, D., Swenson, J.R., Baker, B., van Zyl, L.T., Dorian, P., Abramson, B.L., Abbey, S., Lambert, J.

Funding Agency: CIHR

Funding Amount: \$1,342,996

Duration: 2001-05

Project Title: Father-adolescent interactional patterns associated with adolescent depression: An examination of attachment and communication within the dyad

PI: Manion, I.

Co-Investigators: Demidenko, N.; Lee, C.; Duffy, A.

Funding Agency: OMHF

Funding Amount: \$138,220

Duration: 2004-06

Project Title: The cumulative impacts of everyday discrimination: Compromised neuroendocrine functioning and vulnerability to stress-related psychopathology

PI: Matheson, K.

Co-Investigators: Anisman, H.; Foster, M.

Funding Agency: CIHR

Funding Amount: \$325,542

Duration: 2004-07

Project Title: Peptidergic mediation/modulation of stress response

PI: Merali, Z.

Co-Investigators: n/a

Funding Agency: NSERC

Funding Amount: \$130,000

Duration: 2004-09

Project Title: Motivational enhancement and substance abuse prevention: Evaluating the First Contact-Revised Program for co-morbid youth.

PI: Milin, R.

Co-Investigators: Skilling, T.; Wekerle, C.; Goldstein, A.

Funding Agency: UMRF

Funding Amount: \$23,250

Duration: 2004-05

Grants and Contracts 2005

Project Title: Junior Faculty Research Award

PI: Milin, R.

Co-Investigators: n/a

Funding Agency: UMRF

Funding Amount: \$30,000

Duration: 2004-06

Project Title: L'évaluation des préférences sexuelles à l'aide de la vidéo-oculographie en immersion virtuelle auprès d'un échantillon de sujets agresseurs sexuels d'enfants et d'adolescents.

PI: Renaud, P.

Co-Investigators: Proulx, J.; Rouleau, J.; Bradford, J.; Fedoroff, P.

Funding Agency: CIHR

Funding Amount: \$187,444

Duration: 2004-08

Project Title: Clinical and biogenetic characteristics of treatment response to SSRIs in patients with anxiety disorders

PI: Shlik, J.

Co-Investigators: Koszycki, D.; Du, L.; Hrdina, P.; Albert, P.; Bradwejn, J.

Funding Agency: UMRF

Funding Amount: \$29,990

Duration: 2004-05

Project Title: Clinical and biogenetic characteristics of treatment response to SSRIs in patients with anxiety disorders

PI: Skilling, T.

Co-Investigators: Milin, R.; Wekerle, C.; Goldstein, A.

Funding Agency: CAMH

Funding Amount: \$15,000

Duration: 2004-06

New Grants and Contracts Awarded in 2005

Project Title: The Wellness Project

PI: Bell, R.

Co-Investigators: Haddad, J., Labelle, A., Boyer, P., Middlebro, A., Murata, L.

Funding Agency: CF

Funding Amount: \$100,000.

Duration: 2005-07

Grants and Contracts 2005

Project Title: Role of a functional 5-HT1A receptor gene polymorphism as a risk factor for depression

PI: Bisserbe, J-C.

Co-Investigators: Blier, P., Albert, P., Young, S.

Funding Agency: CIHR

Funding Amount: \$175,870.

Duration: 2005-07

Project Title: Treatment-resistant depression, hippocampus atrophy, and serotonergic genetic polymorphism

PI: Blier, P.

Co-Investigators: Tremblay, A., Smith, A., Merali, Z.

Funding Agency: UMRF

Funding Amount: \$35,100.

Duration: 2005-06

Project Title: Role of the dopamine system in the antidepressant response

PI: Blier, P.

Co-Investigators: n/a

Funding Agency: CIHR

Funding Amount: \$543,700.

Duration: 2005-10

Project Title: Exploration of neurofunctional mechanisms that may contribute to episodic memory impairment in reality testing observed in schizophrenic patients

PI: Boyer, P.

Co-Investigators: n/a

Funding Agency: ROHCF

Funding Amount: \$18,149.

Duration: 2005

Project Title: Identification of risk factors for severe outcome in schizophrenia. Consequences in terms of protection for vulnerable populations

PI: Boyer, P.

Co-Investigators: Albert, P.; Leboyer, M.

Funding Agency: CIHR

Funding Amount: \$5,000.

Duration: 2005

Project Title: Development of a common toolbox for neuropsychological, functional, and genetic analysis of schizophrenic patients

PI: Boyer, P.

Co-Investigators: n/a

Funding Agency: Embassy of France

Funding Amount: \$10,000.

Duration: 2005-07

Grants and Contracts 2005

Project Title: Exploration of neurofunctional mechanisms that may contribute to episodic memory impairment in reality testing observed in schizophrenic patients

PI: Boyer, P.

Co-Investigators: n/a

Funding Agency: CFI

Funding Amount: \$72,532.

Duration: 2005

Project Title: The use of visuospatial navigation as a measure of episodic memory

PI: Boyer, P.

Co-Investigators: Boulay, L.; Roy, P.

Funding Agency: Ontario Schizophrenia Society

Funding Amount: \$13,000

Duration: 2005 - ongoing

Project Title: Using 2D navigation and fMRI to explore patterns of activation in persons with schizophrenia

PI: Boyer, P.

Co-Investigators: Roy, P.; Boulay, L.; Smith, A.

Funding Agency: Ontario Schizophrenia Society

Funding Amount: \$ 13,000

Duration: 2005

Project Title: Using navigation to activate the hippocampal formation during functional magnetic resonance imaging (fMRI): A feasibility study

PI: Boyer, P.

Co-Investigators: Boulay, L.

Funding Agency: Ontario Schizophrenia Society

Funding Amount: \$13,000

Duration: 2005

Project Title: A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of XBD173 in patients with generalized anxiety disorder

PI: Bradwejn, J.

Co-Investigators: Koszycki, D., Shlik, J.

Funding Agency: Novartis

Funding Amount: \$55,000.

Duration: 2005-06

Project Title: Responsiveness of a regional centralized intake to the needs of referring physicians for child and youth mental health services

PI: Cloutier, P.

Co-Investigators: Cappelli, M., Charron, G., Lowe, J., Thatte, S., James, W.

Funding Agency: CHEO Research Institute

Funding Amount: \$29,499

Duration: 2005

Grants and Contracts 2005

Project Title: Cortisol dysregulation as a potential risk factor in children of bipolar parents

PI: Deshauer, D.

Co-Investigators: Duffy, A., Grof, P., Alda, M.

Funding Agency: OMHF

Funding Amount: \$67,550.

Duration: 2005-06

Project Title: Biological and psychological markers in children and adolescents with anxiety disorders

PI: Flament, M.

Co-Investigators: Thatte, S., Koszycki, D.

Funding Agency: UMRF

Funding Amount: \$35,152.

Duration: 2005-06

Project Title: Unsafe sexual practices in public places: An ethnographic study of gay bathhouses

PI: Holmes, D.

Co-Investigators: Gastaldo, D.

Funding Agency: CIHR

Funding Amount: \$69,477.

Duration: 2005-06

Project Title: Effects of acute nicotine administration on arousal, mood, and attention in adolescent smokers with major depressive disorder

PI: Knott, V.

Co-Investigators: Milin, R., Millar, A.

Funding Agency: UMRF

Funding Amount: \$34,999.

Duration: 2005-07

Project Title: Acute antidepressant and neuro-cognitive actions of nicotine during tryptophan depletion-induced depression relapses

PI: Knott, V.

Co-Investigators: Bisserbe, J-C., Blier, P.

Funding Agency: OMHF

Funding Amount: \$149,810.

Duration: 2005-07

Project Title: Effects of smoking history and acute nicotine on mood, arousal, and cognitive responses to tryptophan depletion in depression-prone subjects

PI: Knott, V.

Co-Investigators: Bisserbe, J-C.

Funding Agency: CPRF

Funding Amount: \$200,000.

Duration: 2005-06

Grants and Contracts 2005

Project Title: Randomized controlled trial on the efficacy of interpersonal psychotherapy in depressed women undergoing infertility treatment

PI: Koszycki, D.

Co-Investigators: Bradwejn, J., Bisserbe, J-C., Antochi, S.

Funding Agency: UMRF

Funding Amount: \$34,069.

Duration: 2005-06

Project Title: Open-label, parallel, randomized, dose-proportionality pharmacokinetic study of paliperidone after intramuscular injection of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia

PI: Labelle, A.

Co-Investigators: n/a

Funding Agency: Janssen-Ortho

Funding Amount: \$108,000.

Duration: 2005-06

Project Title: A randomized, double-blind, parallel-group comparative study of flexibly dosed Risperdal Consta (25, 37.5, or 50 mg) administered every 2 weeks in subjects with schizophrenia

PI: Labelle, A.

Co-Investigators: n/a

Funding Agency: Janssen-Ortho

Funding Amount: \$248,680.

Duration: 2005-06

Project Title: Graduate Scholarship: Selective attentional bias and serotonin transporter polymorphisms in social phobia

PI: Millar, A.

Co-Investigators: Knott, V.

Funding Agency: CIHR

Funding Amount: \$10,208.

Duration: 2005

Project Title: Constructing inmates subjectivities: A content analysis of nursing in a forensic psychiatric setting

PI: Perron, A.

Co-Investigators: Holmes, D.

Funding Agency: CIHR

Funding Amount: \$82,500.

Duration: 2005-08

Project Title: Relationship between episodic memory impairment and functional outcome in patients with schizophrenia

PI: Phillips, J.

Co-Investigators: n/a

Funding Agency: ROHCG

Funding Amount: \$902.

Duration: 2005

Grants and Contracts 2005

Project Title: Dysregulated GABA-A, CRH and 5-HT receptor mRNA expression in human depression and suicide

PI: Poulter, M.

Co-Investigators: Anisman, H., Du, L., Merali, Z.

Funding Agency: CIHR

Funding Amount: \$619,310.

Duration: 2004-10

Project Title: Assessment, management and treatment of endocrine disorders in patients with major mental illness

PI: Robertson, S.

Co-Investigators: n/a

Funding Agency: AstraZeneca

Funding Amount: \$10,000.

Duration: 2005

Project Title: Pilot psychiatry/endocrinology clinic at the Royal Ottawa Hospital

PI: Robertson, S.

Co-Investigators: Silverman, M., Coaras, C., Nesbitt, L., Robertson, C., Borracci, G., Antonello, C.

Funding Agency: UMRF

Funding Amount: \$50,000.

Duration: 2005-07

Project Title: Efficacy and tolerability of escitalopram in previously SSRI-non-responsive patients with panic disorder

PI: Shlik, J.

Co-Investigators: n/a

Funding Agency: Lundbeck Canada

Funding Amount: \$181,618.

Duration: 2005-06

Project Title: Evaluation of a partial hospitalization program for adolescents with moderate to severe psychiatric disorders: Effectiveness and predictors of treatment outcome

PI: Thatte, S.

Co-Investigators: Woods, V., Flament, M.

Funding Agency: UMRF

Funding Amount: \$49,966.

Duration: 2005-07

Papers Published in Peer-Reviewed Journals

1. Andrews, G.J., **Holmes, D.**, Poland, B., Lehoux, P., Miller, K.L., Pringle, D., McGilton, K.S.: Airplanes are flying nursing homes: geographies in the concepts and locales of gerontological nursing practice. *J Clin Nurs* 2005; 14:109-120.
2. **Anisman, H., Merali, Z.**, Poulter, M.O., Hayley, S.: Cytokines as a precipitant of depressive illness: animal and human studies. *Curr Pharm Des* 2005; 11:963-972.
3. **Anisman, H., Matheson, K.**: Stress, depression, and anhedonia: caveats concerning animal models. *Neurosci Biobehav Rev* 2005; 29:525-546.
4. **Bergeron, R.**, Coyle, J.T., Tsai, G., Greene, R.W.: NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons. *Neuropsychopharmacology* 2005; 30:7-16.
5. **Blier, P.**, Szabo, S.T.: Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. *J Clin Psychiatry* 2005; 66 Suppl 8:30-40.
6. **Blier, P.**: On the selection and use of atypical antipsychotics in the management of nonpsychotic mood and anxiety disorders. *J Psychiatry Neurosci* 2005; 30:304.
7. **Blier, P.**: Atypical antipsychotics for mood and anxiety disorders: safe and effective adjuncts? *J Psychiatry Neurosci* 2005; 30:232-233.
8. **Boulay, L.J.**, Stip, E., Mancini-Marie, A., Fahim, C., Mendrek, A., Ait-Bentaleb, L. Brain activity in relation to emotional Stimuli: An exploratory fMRI study in schizophrenia patients with and without prominent Auditory Hallucinations. *Schizophrenia Bull* 2005; 31:2: 414.
9. **Bourget, D.**, Gagne, P.: Paternal filicide in Quebec. *J Am Acad Psychiatry Law* 2005; 33:3:354-360.
10. **Bradwejn, J.**, Ahokas, A., Stein, D.J., Salinas, E., Emilien., G., Whitaker, T.: Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. *Br J Psychiatry* 2005; 187:352-359.
11. Brideau, N., Lebouthillier, A., & **Holmes, D.** : Pour en finir avec le silence : utilisation du travail supplémentaire obligatoire comme solution à la pénurie d'infirmières. *Infirmière canadienne* 2005; 6:4: 5-10.
12. Caci, H., Mattei, V., Bayle, F.J, Nadalet, L., Dossios, C., Robert, P., **Boyer, P.**: Impulsivity but not venturosomeness is related to morningness. *Psychiatry Res* 2005; 134:3: 259-65.

Papers Published in Peer-Reviewed Journals

13. Cohen, D., Nicolas, J.D., **Flament, M.F.**, Perisse, D., Dubos, P.F., Bonnot, O., Speranza, M., Graindorge, C., Tordjman, S., Mazet, P.: Clinical relevance of chronic catatonic schizophrenia in children and adolescents: evidence from a prospective naturalistic study. *Schizophr Res* 2005; 76:301-308.
14. **Deshauer, D.**, Fergusson, D., Duffy, A., Albuquerque, J., Grof, P.: Re-evaluation of randomized control trials of lithium monotherapy: a cohort effect. *Bipolar Disord* 2005; 7:382-387.
15. **El Mansari, M., Blier, P.**: Responsiveness of 5-HT(1A) and 5-HT2 receptors in the rat orbitofrontal cortex after long-term serotonin reuptake inhibition. *J Psychiatry Neurosci* 2005; 30:268-274.
16. **El Mansari, M.**, Sanchez, C., Chouvet, G., Renaud, B., Haddjeri, N.: Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. *Neuropsychopharmacology* 2005; 30:1269-1277.
17. Fahim, C, Stip, E., Mancini-Marie, A., Mensour, B., **Boulay, L.J.**, Leroux, J.M., Beaudoin, G., Bourgouin, P., Beauregard, M.: Brain activity during emotionally negative pictures in schizophrenia with and without flat affect: an fMRI study. *Psychiatry Res* 2005; 140:1-15.
18. **Farrell, S.J.**, Huff, J., MacDonald, S.A., Middlebro, A., Walsh, S.: Taking it to the street: a psychiatric outreach service in Canada. *Community Mental Health J* 2005; 41:737-746.
19. Federman, C., **Holmes, D.**: Breaking Bodies into Pieces: Time, Torture and Bio-Power. *Critical Criminology : An International Journal* 2005: 13: 327-345.
20. Feldman, M., Owen, F., Griffiths, D., Tarulli, D., Sales, C., Tardif, C., McQueen-Fentes, G., Atkinson, L., **Fedoroff, P.**, Lunskey, Y.: Facilitating health care and mental health care access of persons with intellectual disabilities: one element of systemic change. *The NADD Bulletin* 2005 : 8:4 71-76.
21. **Firestone, P.**, Dixon, K.L., Nunes, K.L., **Bradford, J.M.**: A comparison of incest offenders based on victim age. *J Am Acad Psychiatry Law* 2005; 33:223-232.
22. **Firestone, P.**, Nunes, K.L., Moulden, H., Broom, I., **Bradford, J.M.**: Hostility and recidivism in sexual offenders. *Arch Sex Behav* 2005; 34:277-283.

Papers Published in Peer-Reviewed Journals

23. Frasure-Smith, N., **Koszycki, D.**, Swenson, J.R., Baker, B., van Zyl, L.T., Laliberté, M.-A., Abramson, B.L., Lambert, J., Gravel, G., Lespérance, F.: Create (Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy): Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease. *Psychosomatic Med* 2005; 68:87-93.
24. Gobbi, G., **Blier, P.**: Effect of neurokinin-1 receptor antagonists on serotonergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs. *Peptides* 2005; 26:1383-1393.
25. Godart, N.T., Curt, F., Perdereau, F., Lang, F., Venisse, J.L., Halfon, O., Bizouard, P., Loas, G., Corcos, M., Jeammet, P., **Flament, M.F.**: Are anxiety or depressive disorders more frequent among one of the anorexia or bulimia nervosa subtype? *Encephale* 2005; 31:279-288.
26. Godart, N.T., Perdereau, F., Jeammet, P., **Flament, M.F.**: Comorbidity between eating disorders and anxiety disorders. First part: methodological review. *Encephale* 2005; 31:44-55.
27. Godart, N.T., Perdereau, F., Jeammet, P., **Flament, M.F.**: Comorbidity between eating disorders and mood disorders: review. *Encephale* 2005; 31:575-587.
28. Godart, N.T., Perdereau, F., Jeammet, P., **Flament, M.F.**: Comorbidity between eating disorders and anxiety disorders: results. *Encephale* 2005; 31:152-161
29. Godart, N.T., Curt, F., Perdereau, F., Lang, F., Venisse, J.L., Halfon, O., Bizouard, P., Loas, G., Corcos, M., Jeammet, P., **Flament, M.F.**: Is depressive disorder linked to anxiety disorder among anorexics and bulimics? *Encephale* 2005; 31:403-411.
30. Greenberg, D.M., **Firestone, P.**, Nunes, K.L., **Bradford, J.M.**, Curry, S.: Biological fathers and stepfathers who molest their daughters: psychological, phallometric, and criminal features. *Sex Abuse* 2005; 17:39-46.
31. Hayley, S., Poulter, M.O., **Merali, Z.**, **Anisman, H.**: The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. *Neuroscience* 2005; 135:659-678.
32. **Holmes, D.**: Governing the captives: forensic psychiatric nursing in corrections. *Perspect Psychiatr Care* 2005; 41:3-13.
33. **Holmes, D.**, Warner, D.: The anatomy of a forbidden desire: men, penetration and semen exchange. *Nurs Inq* 2005; 12:10-20.

Papers Published in Peer-Reviewed Journals

34. **Holmes, D.**, Perron, A., Michaud, G., Montuclard, L., & Hervé, C. : Scission entre le sanitaire et le pénitencier : réflexion critique sur les (im)possibilités du soin infirmier au Canada et en France. *Journal de Réadaptation Médicale* 2005; 25:3: 131-140.
35. King-Andrews, H., **Farrell, S.**: Development of a typology of recommendations posed by a multi-disciplinary consultation outreach team for clients with a dual diagnosis. *The NADD Bull* 2005; 8:6:111-117.
36. **Knott, V.J.**, Raegele, M., Fisher, D., Robertson, N., Millar, A., McIntosh, J., Ilivitsky, V.: Clonidine pre-treatment fails to block acute smoking-induced EEG arousal/mood in cigarette smokers. *Pharmacol Biochem Behav* 2005; 80:161-171.
37. Koido, K., Koks, S., Nikopensius, T., Maron, E., Altmae, S., Heinaste, E., Vabrit, K., Tammekivi, V., Hallast, P., Kurg, A., **Shlik, J.**, Vasar, V., Metspalu, A., Vasar, E.: Polymorphisms in wolframin (WFS1) gene are possibly related to increased risk for mood disorders. *Int J Neuropsychopharmacol* 2005; 8:235-244.
38. **Koszycki, D.**, Torres, S., Swain, J.E., **Bradwejn, J.**: Central cholecystokinin activity in irritable bowel syndrome, panic disorder, and healthy controls. *Psychosom Med* 2005; 67:590-595.
39. Kutcher, S., Brooks, S.J., Gardner, D.M., Honer, B., Kopala, L., **Labelle, A.**, Lalonde, P., Malla, A., Milliken, H., Soni, J., Williams, R.: Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders. *Neuropsychiatric Disease and Treatment*; 2005;1:2 89-108.
40. Liebowitz, M.R., Mangano, R.M., **Bradwejn, J.**, Asnis, G.: A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. *J Clin Psychiatry* 2005; 66:238-247.
41. Loas, G., Guilbaud, O., Perez-Diaz, F., Verrier, A., Stephan, P., Lang, F., Bizouard, P., Venisse, J.L., Corcos, M., **Flament, M.F.**, Jeammet, P.: Dependency and suicidality in addictive disorders. *Psychiatry Res* 2005; 137:103-111.
42. Mantler, J., Matejcek, A., **Matheson, K, Anisman, H.**: Coping with employment uncertainty: a comparison of employed and unemployed workers. *J Occup Health Psychol* 2005; 10:200-209.
43. Maron, E., Nikopensius, T., Koks, S., Altmae, S., Heinaste, E., Vabrit, K., Tammekivi, V., Hallast, P., Koido, K., Kurg, A., Metspalu, A., Vasar, E., Vasar, V., **Shlik, J.** : Association study of 90 candidate gene polymorphisms in panic disorder. *Psychiatr Genet* 2005; 15:17-24.

Papers Published in Peer-Reviewed Journals

44. Maron, E., Lang, A., Tasa, G., Liivlaid, L., Toru, I., Must, A., Vasar, V., **Shlik, J.**: Associations between serotonin-related gene polymorphisms and panic disorder. *Int J Neuropsychopharmacol* 2005; 8:261-266.
45. Martina, M., Turcotte, M.E., Halman, S., Tsai, G., Tiberi, M., Coyle, J.T., **Bergeron R.**: Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice. *J Physiol* 2005; 563:777-793.
46. **Matheson, K., Kelly, O.**, Cole, B., Tannenbaum, B., Dodd, C., **Anisman, H.** : Parental bonding and depressive affect: the mediating role of coping resources. *Br J Soc Psychol* 2005; 44:371-395.
47. O'Brien, A.M., **Farrell, S.J.**: Community treatment orders: profile of a Canadian experience. *Can J Psychiatry* 2005; 50:27-30.
48. O'Byrne, P., **Holmes, D.**: Re-evaluating current public health policy: alternative public health nursing approaches to sexually transmitted infection testing for teens and males who have sex with males. *Public Health Nurs* 2005; 22:523-528.
49. Pelissolo, A., **Boyer, P.**, Fouget, F., Servant, D., Stiti, S., Richard-Buthe, C.: Factors Associated With Disability In Social Anxiety Disorder. *Int J Neuropsychopharmacol* 2005;57(6): 31.
50. Perron, A., Fluet, C., **Holmes, D.**: Agents of care and agents of the state: bio-power and nursing practice. *J Adv Nurs* 2005; 50:536-544.
51. Poland, B. Lehoux, P., **Holmes D.**, Andrews, G.: How place matters: unpacking technology and power in health and social care. *Health Soc Care Community* 2005; 13:170-180.
52. **Prince, P.N.**, Gerber, G.J.: Subjective well-being and community integration among clients of assertive community treatment. *Qual Life Res* 2005; 14:161-169.
53. Renaud, P., Proulx, J., Rouleau, J., Bouchard, S., Madrigano, G., **Bradford, J., Fedoroff, P.**: The recording of observational behaviours in virtual immersion: A new clinical tool to address the problem of sexual preferences with paraphilias. *Annual review of Cybertherapy and Telemedicine*. 2005; 3: 85-92.
54. Rothe, C., **Koszycki, D., Bradwejn, J.**, King, N., De Luca, V., Tharmalingam, S., Macciardi, F., Deckert, J., Kennedy, J.: Association of the val 158 met catechol o-methyltransferase genetic polymorphism with panic disorder. *Neuropsychopharmacology* (Epub ahead of print).
55. Schachter, H.M., Kourad ,K., **Merali, Z.**, Lumb, A., Tran, K., Miguelez, M.: Effects of omega-3 fatty acids on mental health. *Evid Rep Technol Assess (Summ.)* 2005; 1-11.

Papers Published in Peer-Reviewed Journals

56. Simeon, J., Nixon, M.K., **Milin, R.**, Jovanovich, R., Walker, S.: Open-Label Trial of St. John's Wort in Adolescent Depression. *Journal of Child and Adolescent Psychopharmacology* 2005; 2:298-301.
57. Speranza, M., Corcos, M., Loas, G., Stephan, P., Guilbaud, O., Perez-Diaz, F., Venisse, J.L., Bizouard, P., Halfon, O., **Flament, M.**, Jeammet, P.: Depressive personality imensions and alexithymia in eating disorders. *Psychiatry Res.* 2005; 135:153-163.
58. Steiner, M., Hirschberg, A.L., **Bergeron, R.**, Holland, F., Gee, M.D., Van Erp, E.: Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. *Am J Obstet Gynecol* 2005; 193:352-36.
59. Stip, E., **Boulay, L.J.** : Aspects cognitifs des troubles bipolaires. *L'Éccéphale*, 2005; 31:2:25-32.
60. Stip, E., Chouinard S., **Boulay, L.J.**: On the trail of a cognitive enhancer for the treatment of schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 2005; 29:219-232.
61. Tharmalingam, S., King, N., De Luca, V., Rothe, C., **Koszycki, D.**, **Bradwejn, J.**, Macciardi, F., Kennedy, JL.: Investigation of the corticotropin-releasing hormone receptor 2 gene in panic disorder. *Psychiatric Genetics*. (Epub ahead of print).
62. Viard, A., **Flament, M.F.**, Artiges, E., Dehaene, S., Naccache, L., Cohen, D., Mazet, P. Mouren, M.C., Martinot, J.L: Cognitive control in childhood-onset obsessive-compulsive disorder: a functional MRI study. *Psychol Med* 2005; 35:1007-1017.
63. Voyer, P., Verreault, R., Cappeliez, P., **Holmes, D.**, Mengue, P.N.: Symptoms of psychological distress among older adults in Canadian long-term care centres. *Aging Ment Health* 2005 9:542-554.
64. Wijeweera, P., Arnason, JT., **Koszycki, D.**, **Merali, Z.**: Evaluation of anxiolytic properties of Gotukola-(centella asiatica) extracts and asiaticoside in rat behavioural models. *Phytomedicine*. (Epub ahead of print).
65. Xiong, L., Rouleau, G.A., DeLisi, L.E., St-Onge, J., Najafee, R., Rivière, J.B., Benkelfat, C., Tabbane, K., Fathalli, F., Danics, A., **Labelle, A.**, Lal, S., Joober, R.: CAA insertion polymorphism in the 3'UTR of Nogo gene on 2p14 is not associated with schizophrenia. *Molecular Brain Research* 2005; 133:153-156.

Other Publications

Published Abstracts

1. **Bergeron, R.**, Tremblay, P., Ward, H.E., Hébert, C., **Blier, P.**: Antidepressant drug combination from treatment initiation to improve therapeutic response in major depression. *Neuropsychopharmacology* 30: S98, 2005.
2. Berney, A., Leyton, M., Gravel, P., Rosa-Neto, P., Todorov, C., Sookman, D., Pinard, G., **Blier, P.**, Diksic, M., Benkelfat, C.: Brain regional α -[¹¹C]methyl-L-Tryptophan trapping in medication-free patients with obsessive compulsive disorder. *Neuropsychopharmacology* 30: S97, 2005.
3. **Blier, P.**: Neuropsychopharmacology: Bridging animal and human studies. *European Neuropsychopharmacology* 15 (Suppl 1):S30, 2005.
4. **Blier, P.**: Pre-clinical rationale for combined treatment of depression. *New Clinical Drug Evaluation Unit* 45: 89, 2005.
5. **Blier, P.**: What can we learn from pre-clinical studies of antidepressants? *International Journal of Psychiatry in Clinical Practice* 9: 306-307, 2005.
6. **Blier, P.**: SNRIs – Vive la différence! *International Journal of Psychiatry in Clinical Practice* 9: 310, 2005.
7. **Blier, P.**, **Dremencov, E.**, **El Mansari, M.**: Pharmacological dissection of the effect of risperidone on SSRI-induced changes of norepinephrine neuronal firing. *Neuropsychopharmacology* 30: S99, 2005.
8. **Boyer P.**: Understanding the genetics of Panic Disorder. *The World Journal of Biological Psychiatry*, 6: S1, 23, 2005.
9. **Bradwejn, J.**, **Koszycki, D.**, Segal, Z.: Randomized controlled trial of acute and extension treatment with sertraline and self-administered cognitive behaviour therapy, alone or in combination, in panic disorder. ECNP Meeting, Amsterdam, The Netherlands, October 2005.
10. Byrne, A., Fung, I., **Flament, M.F.**: Evidence-based pharmacological treatment for children and adolescents with anxiety disorders. 2nd Annual Meeting of the Anxiety Disorders Association of Canada. Markham, Ontario. May 2005.
11. Desan, P., Michalak, E., Weinstein, A., Lam, E., Tam, Y., Meesters, M., Ruiter, M., **Horn, E.**, Stinson, L., **Telner, J.**, Boivin, D., Iskander, H., Bowen, R.: A controlled trial of the Litebook light-emitting diode (LED) light therapy device for the treatment of seasonal affective disorder (SAD). 17th Annual Meeting of the Society for Light Treatment and Biological Rhythms (SLTBR). Eindhoven, The Netherlands, July, 2005.

Other Publications

12. **Dremencov, E., El Mansari, M., Blier, P.** : Risperidone reverses the escitalopram-induced inhibition of locus coeruleus norepinephrine neuron firing: a 5-HT_{2A} receptor-mediated effect. *Society for Neuroscience*, 35:677.16, 2005.
13. **Douglass, A.B., Orr, L., Busby, K., Vadneau, A., Fathi, K.**: Sleep state misperception in a psychiatric hospital outpatient clinic. *Sleep* 28 (Supp.1): A241, 2005.
14. **Duffy, A., Alda, M., Demidenko, N., Milin, R., Kutcher, S., MacQueen, G., Grof, P.**: Heterogeneity in Early-onset Bipolar Disorders: Convergent Findings from Prospective Studies of the Offspring of Well-characterized Bipolar Parents. American Academy of Child and Adolescent Psychiatry and Canadian Academy of Child Psychiatry Joint Annual Meeting, Toronto, October, 2005.
15. **Farrell, S., Votta, E.**: The comfort of home: Gendered differences in coping styles among housed and homeless adolescents. Canadian Psychological Association, Montreal, Quebec, May, 2005.
16. **Farrell, S.**: Developing a research culture within a team of community-based service providers. National Conference on Homeless, Toronto, Ontario, May 2005.
17. **Farrell, S., Votta, E.**: Youth homelessness: Understanding opportunities for primary, secondary and tertiary and prevention through housing and gender-based comparisons. National Conference on Homeless, Toronto, Ontario, May 2005.
18. **Fedoroff, P., Curry S., Madigrano, G., Cunningham, C., Korovessis, A., Bradford J., Richards, D., Griffiths, D.**: Validation of risk assessment tools for individuals with problematic sexual behaviour and developmental delay: preliminary results. International Academy of Sex Research Thirty-First Annual Meeting, Ottawa, Ontario. p. 29.
19. **Fedoroff, P., Curry, S., Madigrano, G., Cunningham, C., Bradford J.**: Comparison of VRAG/SORAG items in a sample of developmentally delayed sex offenders and non delayed sex offenders. International Academy of Sex Research Thirty-First Annual Meeting, Ottawa, Ontario. p. 30.
20. **Flament, M.F., Schacter, H., Nguyen, H., Cuzner, C., Sartorius, N., Wasserman, D., Renschmidt, H.**: How can Prevention Apply to Child and Adolescents Mental Health? A world wide review of evidence-based programs. 37th Banff International Conference on Behavioural Science, Banff, Alberta. March 20-23, 2005.
21. **Fossati, P., Boyer, P.**: Relevance of neuroplasticity and cellular resilience in bipolar disorder and depression: Evidence from neuroimaging and cognitive studies. *European Neuropsychopharmacology*, 2004, 14, S3, 123.

Other Publications

22. Freeland, A., O' Brien, AM., **Farrell, S.**: Community treatment orders with and without Assertive Community Treatment. International Academy of Law and Mental Health, Paris, France, July, 2005.
23. **Holmes, D.**, Perron, A.: American Nursing on the Edge: The Use of Nurses in the Capital Punishment Process. International Academy of Law and Mental Health. 29th International Congress on Law and Mental Health. Dordrecht: Springer, 2005.
24. Huff, J., **Farrell, S.**: The effectiveness of occupational therapy with people at risk of homelessness. National Conference on Homeless, Toronto, Ontario, May 2005.
25. **Knott, V.**, Millar, A., McIntosh, J., Fisher, D., Illivitsky V., **Horn, E.**: Separate and combined effects of nicotine and an NMDA receptor antagonist on early sensory processing in smokers and non-smokers. 45th Annual Meeting of Society for Psychophysiological Research. Lisbon, Portugal, September 2005.
26. **Koszycki, D.**, Zwanzger, P., **Merali, Z.**, **Bradwejn, J.**: Heart rate variability and cortisol response to a stressor in children at high and low genetic risk for panic disorder. American Society for Psychosomatic Medicine, Vancouver, British Columbia, March, 2005.
27. **Koszycki, D.**, **Shlik, J.**, **Bradwejn, J.**: Influence of personality on behavioral and cardiovascular response to cholecystokinin-tetrapeptide in healthy volunteers. 18th ECNP Congress, Amsterdam, The Netherlands, October, 22-26, 2005.
28. Laroche, M., Baillot, D., Furino, C., Buchholz, A., Henderson, K., Goldfield, G., **Flament, M.F.**: Troubles des conduits alimentaires et obésité : Différences entre adolescents canadiens, américains et français. Annual Meeting of the Canadian Psychological Association, Montreal, Quebec, June, 2005.
29. O' Brien, AM., **Farrell, S.**, Freeland, A.: Psychiatrist's use of community treatment orders. CPA, Vancouver, British Columbia, November 2005.
30. O' Brien, AM., **Farrell, S.**, Freeland, A.: Community treatment orders in the Champlain Health District. International Academy of Law and Mental Health, Paris, France, July, 2005.
31. Maron, E., Lang, A., Tasa, G., Liivlaid, L., Toru, I., Must, A., Vasar, V., **Shlik, J.**: Association study of serotonin system genes in panic disorder. 18th ECNP Congress, Amsterdam, The Netherlands, October 22-26, 2005.
32. **Milin, R.**: Youth Mental Health and Addictions. 6th National Conference on Shared Mental Health Care, Ottawa, Ontario, June, 2005.

Other Publications

33. **Milin, R.**, Manion, I., Dare, G.: Prospective assessment of cannabis withdrawal in adolescents. American Academy of Child and Adolescent Psychiatry and Canadian Academy of Child Psychiatry Joint Annual Meeting, Toronto, Ontario. October, 2005.
34. **Milin, R.**, Manion, I., Dare, G.: Prospective assessment of cannabis withdrawal in adolescents: a pilot study. American Academy of Addiction Psychiatry, 16th Annual Meeting and Symposium, Scottsdale, Arizona, December, 2005.
35. Mores, C., **Boyer, P.**, Denis, M., Daniel, M.P., Fossati, P., Jouvent, R.: Visual-spatial memory and schizophrenia. Centre National de la Recherche Scientifique (CNRS)., Paris, France, Annual General Meeting, 2005.
36. Nordin, C., Ekback, M., Sjodin, I., **Shlik, J.**: Increased 5-HT/5-HIAA ratio in CSF during tryptophan depletion. 18th ECNP Congress, Amsterdam, The Netherlands, October 22-26, 2005.
37. Remington, G., Mamo, D., **Labelle, A.**, Reiss, J., Shammi, C., Mann, S., Mannaert, E., Kapur, S.: Peak and trough dopamine D2 receptor occupancy for long-acting injectable risperidone: a PET study. *Schizophr Bull* 2005; 31: 444.
38. **Shlik, J.**, Maron, E.: Screening for bipolarity in patients with panic disorder. 25th ADAA. Seattle, Washington. *Depression and Anxiety*, March 17-20, 2005; 22:234.
39. **Shlik, J.**, Maron, E., Moido, K., Nikopensus, T., Koks, S.: Association between CCK-related gene polymorphisms and personality traits. 28th Annual Meeting of the CCNP. St. John's, Newfoundland, July 2-5, 2005.
40. **Shlik, J.**, Koido, K., Nikopensus, T., Maron, E., Koks, S.: Associations between genetic polymorphisms of cholecystokinin and its receptors and personality traits. 18th ECNP Congress, Amsterdam, The Netherlands, 22-26 October, 2005.
41. **Shlik, J.**: Cholecystokinin and personality. 18th ECNP Congress, Amsterdam, The Netherlands, 22-26 October, 2005.
42. **Telner, J.**, Ravindran, R., Bhatla, R., Cameron, C., **Horn, E.**: Effects of medication and cognitive behavior therapy, alone and in combination on pathological gambling. European Association of Cognitive Behavior Therapy, Thessaioniki, Greece, 2005.
43. Toru, I., **Shlik, J.**, Maron, E., Vasar, V., Nutt, D.J.: Acute tryptophan depletion does not modify the response to CCK-4 challenge in patients with panic disorder after citalopram treatment. 18th ECNP Congress, Amsterdam, The Netherlands, October 22-26, 2005.

Other Publications

44. Villeneuve, J., Demers, MF., Almeras, N., Proulx, I., **Labelle, A., Bourget, D., Mottard, JP., Roy, M.A., Bouchard, R.H.** : Advantages of quetiapine on sexual dysfunctions: a switch study." International Congress on Schizophrenia Research. Savannah, April, 2005.

Book Chapters

1. **Blier, P.**: Medication combination and augmentation strategies in the treatment of major depression. In: The American Psychiatric Publishing Textbook of Mood Disorders. (Eds): Dan J Stein, David J Kupfer, Alan F Schatzberg. American Psychiatric Publishing Inc, Washington DC, 2005, pp. 509-524.
2. **Boyer, P.**: (Ed.) Generalized Anxiety Disorder (in French). Vol. 1. John Libbey Publishing. Paris, 2005, pp. 137.
3. **Bradford, J.M., Fedoroff, P.**: The pharmacologic treatment of the juvenile sex offender, 2nd Edition. In: H. Barbaree, W. Marshall (Eds.), The Juvenile Sex Offender, Guilford Publications Inc., New York, 2005.
4. **Flament, M.F., Furino, C., Godart, N.**: Evidence-based pharmacological treatment of eating disorders. In: Stein D., Stahl S., Lerer B. (Eds): Evidence-Based Psychopharmacology. Cambridge University Press, 2005, pp. 204-254.
5. **Holmes, D., Federman, C.**: Unethical Nursing Practices in the United States. In: N. Fisanick, The Ethics of Capital Punishment. Detroit: Greehaven Press, 2005.
6. **Holmes, D., Perron, A.** : Populations vulnérables et santé communautaire. In: G. Carroll (Ed). Soins infirmiers en santé communautaire. Chenelière Éditions, 2005.
7. Schacter, H. M., Konrad, K., **Merali, Z., Lumb, A., Tran, K., Miguelez, M.**: Effect of Omega-3 Fatty Acids on Mental Health. *Evidence Report/Technology Assessment* No. 116 AHRQ Publication No. 05-EO22-2. Agency for Healthcare Research and Quality, July, 2005.
8. Stip, E., **Boulay, L.J.** : Aspects cognitifs des troubles bipolaires. In : *Troubles bipolaires: pratiques, recherche et perspectives*. Ed Marion Leboyer. pp. 211-245. John Libbey Eurotext: Paris, 2005.

Non-Peer Reviewed Journals

1. **Kelly, O.**, (2005) Lawyers and Anxiety: Three Cases Studies. The Canadian Bar Association. Available at: [http:// www.cba.org/cba/PracticeLink/BWL/anxiety.aspx](http://www.cba.org/cba/PracticeLink/BWL/anxiety.aspx).

Invited Lectures, Participation in Public Forums

1. **Blier, P.:** The inextricable relationship between norepinephrine and serotonin. Winter Brain Research Conference. Breckenridge, Colorado, January 24, 2005.
2. **Blier, P.:** Mechanism of action and pharmacology of escitalopram. National Symposium on Depression. Athens, Greece, February 5, 2005.
3. **Blier, P.:** What's new in the psychopharmacology of depression? University of Western Ontario, Grand Rounds. February 10, 2005.
4. **Blier, P.:** Bases neurologiques de la réponse antidépressive: études fondamentales et cliniques, Centre Hospitalier Universitaire de Sherbrooke, February 11, 2005.
5. **Blier, P.:** Neuropsychopharmacology: Bridging animal and human studies. European College of Neuropsychopharmacology Workshop for Young Scientists, Nice, France, March 5, 2005.
6. **Blier, P.:** Mechanism of action of new antidepressants – What can we expect? Hurghada, Egypt, April 7, 2005.
7. **Blier, P.:** Depression and generalized anxiety disorder: A clinical management review. Irish Consultant Psychiatrists Meeting. The Institute of Psychiatry at the Maudsley London, England. April 9, 2005.
8. **Blier, P.:** Onset of action: A key discussion factor in antidepressant therapy. Chilean Society of Biological Psychiatry Santiago, Chile. May 2, 2005.
9. **Blier, P.:** Mechanisms of action of antidepressants and clinical use of antidepressants: A focus on mirtazapine. Santiago, Chile, May 2, 2005
10. **Blier, P.:** Mechanism of action and the clinical use of antidepressants: A focus on mirtazapine. Columbian Society of Biological Psychiatry. Cali, Columbia, May 3, 2005.
11. **Blier, P.:** Mechanisms of action of antidepressants: From neurobiological background to clinical evidence. Columbian Society of Biological Psychiatry. Bogota, Columbia, May 4, 2005.
12. **Blier, P.:** Mechanism of action of antidepressants: From neurobiological background to clinical evidence, Venezuelan Society of Psychiatry. Caracas, Venezuela. May 6, 2005.
13. **Blier, P.:** Mechanism of action of antidepressants: From neurobiological background to clinical evidence, Peruvian College of Psychiatry. Lima, Peru, May 6, 2005.
14. **Blier, P.:** Onset of Action: A key discussion factor in antidepressant therapy. Peruvian Society of Psychiatry, Lima, Peru, May 7, 2005.

Invited Lectures, Participation in Public Forums

15. **Blier, P.** : Les interactions entre les neurotransmetteurs : La clé du succès dans le traitement de la dépression. Centre Hospitalier Universitaire de Québec, Département de Psychiatrie. Québec, Québec, May 26, 2005.
16. **Blier, P.**: Does mechanism-based combination treatment improve a trial and error sequential monotherapy in treating adult depression? Pre-clinical rationale for combined treatment of depression. New Clinical Drug Evaluation Unit. Boca Raton, Florida. June 8, 2005.
17. **Blier, P.**: Depression as a systemic illness. Asia-Pacific Neuroscience Summit. Chinese Society of Psychiatry. Beijing, China. June 19, 2005.
18. **Blier, P.**: Bases Neurobiológicas de la Respuesta al Tratamiento Antidepresivo: Del Laboratorio a la Clínica. Simposio Internacional de Neurociencias, Buenos Aires, Argentina, August 29, 2005.
19. **Blier, P.**: Neurobiological bases for the antidepressant response: from the bench to the clinical setting. University of Alberta, Edmonton, Alberta. October 7, 2005.
20. **Blier, P.**: Contribution of basic neuroscience research findings to the treatment of depression. Congress of Pharmacology, Plenary Lecture. Caracas, Venezuela, October 29, 2005.
21. **Blier, P.**: Neurobiological basis for the antidepressant response: Newer generation agents. Novel Neuropharmacological Approaches to Treat Depression Symposium. Latino-American Congress of Pharmacology. Caracas, Venezuela, October 30, 2005.
22. **Blier, P.**: Serotonin and norepinephrine reuptake inhibitors. International Forum on the Management of Affective Disorders Symposium. Vienna, Austria. November 10, 2005.
23. **Blier, P.**: New Antidepressants – how do they work and how effective are they? What can we learn from pre-clinical studies of antidepressants? International Forum on the Management of Affective Disorders Symposium. Vienna, Austria. November 10, 2005.
24. **Blier, P.**: Neurobiological bases for the antidepressant response: from the bench to the clinical setting. Queen's University, Kingston, Ontario. November 12, 2005.
25. **Boulay, L.J.**: Brain activity in relation to emotional stimuli: An exploratory fMRI study in schizophrenia patients with and without prominent auditory hallucinations. Presented at the Eli Lilly Canada Chair in Schizophrenia Research Annual Scientific Day, Les Impatients, Edifice du Bon Pasteur, Montreal, Quebec. February 17th 2005.
26. **Bourget, D.**: Program Director and Coordinator of the 10th Annual CAPL Conference - CPA Forensic Section Winter Meeting (Mont Tremblant, Quebec). February 27 - March 2, 2005.

Invited Lectures, Participation in Public Forums

27. **Bourget, D.:** The NCR defense: A psychiatric perspective. The Nova Scotia Criminal Lawyers Association Conference. Halifax, Nova Scotia, December 2, 2005.
28. **Bourget, D.:** Law and Psychiatry Interface. 55th Annual Meeting. Vancouver, BC, November 4, 2005.
29. **Bradwejn, J.:** Grand Rounds, Dept. of Psychiatry, Queen's University. Kingston, Ontario, May 20, 2005.
30. **Bradwejn, J.:** Complementary/Alternative Medicine Approaches to Anxiety Disorders. Harvard Medical School, Boston, Massachusetts, June 24-25, 2005.
31. **Bradwejn, J.:** 18th ECNP Congress, Expert presentation at the Brainstorming Session: Update of Clinical and genetic aspects of CCK research. Amsterdam, Netherlands. October 25, 2005.
32. **Boyer, P.:** Neuroplasticity, comparison of post seizures and post depressive modifications. 2nd International Meeting on Connections of the Central Nervous System, an Interdisciplinary Approach. Bordeaux, France, March 19, 2005.
33. **Boyer, P.:** Bipolar spectrum and Schizophrenia: continuity or separated entities; pro and cons. 13th European congress of psychiatry, Munich, Germany, April 4-8, 2005.
34. **Boyer, P.:** Understanding the genetics of Panic Disorder. 8th World Congress of Biological Psychiatry, Vienna, Austria, July 1-4, 2005.
35. **Boyer, P.:** The neurobiology of the hippocampus and of the amygdale nuclei. CME course. Allen Memorial Hospital, McGill University, Montreal, Quebec, September 9, 2005.
36. **Boyer, P.:** The neurobiology of the hippocampus and of the amygdale nuclei. CME course. Hopital Maisonneuve et Rosemont (in French), Montreal, Quebec, September 22, 2005.
37. **Boyer, P.:** The role of the amygdala and the hippocampus in the neurobiology of stress and anxiety (in French). Association Médicale des Psychiatres du Québec, Annual Meeting, Quebec, November, 2005.
38. **Boyer, P.:** The neurobiology of the hippocampus and of the amygdale nuclei. CME course. Centre Hospitalier Universitaire de Québec, Quebec City, November 17, 2005.
39. **Boyer, P.:** The role of the amygdala and the hippocampus in the neurobiology of stress and anxiety (in French). Association Médicale des Psychiatres du Québec, Annual Meeting, Quebec, November 30, 2005.

Invited Lectures, Participation in Public Forums

40. **Boyer, P.:** The neurobiology of the hippocampus and of the amygdale nuclei. CME course. Hopital Louis F Lafontaine, Montreal, Quebec, December 20, 2005.
41. Coyte, P.: **Holmes, D.** (2005). Unmasking regional variations in health care finance: Troubled times: Sustainable Development and Governance in the Age of Extremes. International Conference. Karachi, Pakistan. European College of Neuropsychopharmacology February 11, 2005.
42. **Fedoroff, P.:** Sex and Insanity. Timmins and District Hospital Professional Staff In-Service Presentation. Timmins, Ontario.
43. **Fedoroff, P.:** Sex and Violence. World Association of Sexology 17th Congress (Plenary Address and Symposium), Montreal, Quebec.
44. **Fedoroff, P.:** The Ontario Review Board. Timmins and District Hospital Professional Staff In-Service Presentation, Timmins, Ontario.
45. **Fedoroff, P.:** Dangerous and Long Term Offenders from a Psychiatric Perspective. AAPL Annual Meeting, October 27, 2005.
46. **Fedoroff, P.:** Risk Assessment in Men with Intellectual Disability. Department of Psychiatry, Academic and Research Day, December 2, 2005, Ottawa, Ontario.
47. **Fedoroff, P.:** Risk Assessment in Sex Offenders with Intellectual Disability. APPL Annual Conference. Montreal, Quebec. October 30, 2005.
48. **Fedoroff, P.** Curry, S., Madigrano, G., Cunningham, C., **Bradford, J.:** Comparison of VRAG/SORAG items in a sample of developmentally delayed sex offenders and non delayed sex offenders. International Academy of Sex Research Thirty-First Annual Meeting. (Poster Presentation).
49. **Fedoroff, P.,** Curry, S., Madigrano, G., Cunningham, C., Korovessis, A., **Bradford, J.,** Richards, D., Griffiths, D.: Validation of risk assessment tools for individuals with problematic sexual behaviour and developmental delay: preliminary results. International Academy of Sex Research Thirty-First Annual Meeting. (Poster Presentation).
50. **Flament, M.F.,** Most common anxiety disorders. Anxiety in children: From risk to resilience. The Royal Ottawa Health Care Group. Ottawa, Ontario. February 10, 2005.
51. **Flament, M. F.,** Dépression et suicide : Efficacité des traitements et des programmes de prévention chez l'enfant et l'adolescent. Hôpital Rivière-des-Prairies. Montreal, Quebec, May 19, 2005.

Invited Lectures, Participation in Public Forums

52. **Flament, M.F.**, Risk Factors for eating disorders. The Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario. May 27, 2005.
53. **Flament, M.F.**, Halmi, K. Workshop on eating disorders. 8th World congress of Biological Psychiatry, Vienna, Austria. June 28- July3, 2005.
54. **Holmes, D.**: Keynote speaker: Organizations as Evil Structures. International Conference – Custody and Caring. University of Saskatchewan, Saskatchewan. 2005.
55. **Holmes, D.**, Perron, A.: American nursing on the edge: The use of nurses in the capital punishment process. International Academy of Law and Mental Health. 29th International Congress on Law and Mental Health, La Sorbonne, Paris, 2005.
56. Johnston, M., **Prince, P.N.**: Shared care knowledge transfer through an interdisciplinary learning forum. 6th National Conference on Shared Mental Health Care, Ottawa, June 2005.
57. **Koszycki, D.**: Royal Ottawa Hospital in conjunction with the University of Ottawa Institute of Mental Health Research and Children's Hospital for Eastern Ontario. Children and Anxiety: From Risk to Resilience. (Public Forum). Ottawa, Ontario. February 10, 2005.
58. **Labelle A.** : Impacts sociaux de la schizophrénie et nouvelles avenues thérapeutiques. Hopital Robert Giffard, Québec, Québec April 29, 2005.
59. **Labelle A.** : Impacts sociaux de la schizophrénie et nouvelles avenues thérapeutiques, Restaurant La Fenouillere, Sainte Foy, Québec, April 28, 2005.
60. **Labelle A.** : Schizophrénie et prévention des rechutes. Hopital St-Charles-Borromée, Joliette, Québec, May 25, 2005.
61. **Labelle A.**: Special Rounds - Consta for Clinical Use. Royal Ottawa Hospital, Ottawa, Ontario, January 19, 2005.
62. Phillips, J.L., **Boulay, L.**, Mores, M., Denis, M., **Boyer, P.**: Using navigation and fMRI to investigate episodic memory impairment in schizophrenia. 26th Annual and Teaching Day, Royal Ottawa Hospital, Ottawa, Ontario. December 2, 2005.
63. Renaud, P., Proulx, J., Rouleau, J.L., Bouchard, S., Granger, L., **Bradford, J., Fedoroff, P.**, Madigrano, G.: The recording of gazing responses in virtual immersion: A new clinical tool to assess sexual preference in paraphilias. Conférence présentée dans le cadre de *Cybertherapy*, Bâle, Suisse, June 7-10, 2005.

Invited Lectures, Participation in Public Forums

64. Renaud, P., Proulx, J., Rouleau, J.-L., Granger, L., **Bradford, J., Fedoroff, P.,** Madrigrano, G., Bouchard, S.: L'évaluation des préférences sexuelles à l'aide de la vidéo-oculographie utilisée en immersion virtuelle. Conférence présentée dans le cadre de CIFAS (2005): L'agression sexuelle, coopérer au-delà des frontières, Gatineau, Quebec, October 4-8, 2005.
65. Renaud, P., Proulx, J., Rouleau, J.-L., Granger, L., Johnson, J., **Fedoroff, P. Bradford, J.,** Décarie, J., Bouchard, S. : Designing and testing virtual characters to probe the mind of sex criminals. Conférence présentée dans le cadre de Virtuality 2005: 6th International conference on digital cinema, virtual reality, computer graphics, 3D animation and special effects (sponsorisé par ACM Siggraph), November 3-6, 2005.
66. **Shlik J.:** Cholecystokinin and personality. Expert presentation at the Brainstorming Session: Update on clinical and genetic aspects of CCL research. Amsterdam 18th ECNP Congress, The Netherlands. October 22-26, 2005.

Media Presentations

1. **Blier, P.** has participated in numerous interviews for local television, including CBC, CJOH with Leigh Chapple and the A-Channel (formerly the New RO); radio (CBC French Radio and Television, CFRA); as well as, print for The Ottawa Citizen, Research Perspectives and Discoveries in the Making, National Review of Medicine (a bi-weekly journal for Canadian physicians) covering such topics as depression and psychopharmacological issues, SSRIs and other antidepressants, and ongoing research studies.
2. **Bradford, J.** CTV NewsNet "Crimes of Passion".
3. **Bradford, J.** CJOH, CTV Newsline. "Special Report: Violence". March 8-20, 2005.
4. **Bradford, J.** 640 AM Toronto radio interview with Sarah Meehan. "Karla Homolka".
5. **Bradwejn, J.** TV Rogers, A Campagne de financement de l'Hôpital Royal d'Ottawa, Ottawa, Ontario, May 5, 2005.
6. **Bradwejn, J., and Koszycki, D.** CBC. The Nature of Things (David Suzuki). Passion and Fury - The Emotional Brain. National and International Broadcasts. February 26, 2005.
7. **Bradwejn, J.** CJOH-Ottawa Nightline, "A Funding from Provincial Government". Ottawa, Ontario. July 16, 2005.
8. **Bradwejn, J.** TFO-TV Ontario. Moments anxieux II, Multipart documentary, Multiple broadcasts. Ottawa, Ontario. November 5 – December 10, 2005.
9. **Douglass, A.** Radio. Dr. Barry Dworkin's Sunday House Call. Interview and listener call-in program regarding general sleep disorders and insomnia. Ottawa, Ontario, October 2005.
10. **Fedoroff, P.** Japan Public Television, Expert Commentary. The Treatment of Sex Offenders.
11. **Fedoroff, P.** CNN Paula Zahn, Expert Commentary. Sex Offenders.
12. **Fedoroff, P.** The Globe and Mail, Expert Commentary. Spouses of Sex Offenders.
13. **Fedoroff, P.** The Ottawa Citizen, Feature Profile: Helping Pedophiles Before They Offend.
14. **Fedoroff, P.** Global Television, Expert Commentary. Can Pedophiles Be Cured?
15. **Flament, M. F.** The New RO. Eating Disorders in Youth. Ottawa, Ontario. April 2005.
16. **Kelly, O.** CKCU. Sound Mind (Heather Bruce). Stress and Coping.
17. **Koszycki, D.** CJOH News. Series on stress. February 28 and March 1 and 2, 2005.

Media Presentations

18. **Koszycki, D.** Ottawa Sun (Geoff Matthews). Claustrophobia. Ottawa, Ontario. March 6, 2005.
19. **Koszycki, D.** Ottawa Sun (Nelly Elayoubi). Acrophobia, Ottawa, Ontario. March 12, 2005.
20. **Koszycki, D.** Le Devoir (Mylène Tremblay). La méditation en guise de traitement de première ligne. Ottawa, Ontario. February 26, 2005.
21. **Koszycki, D.** CTV. Three part series on phobias (Catherine Latheme). Ottawa, Ontario. November 2005.
22. **Merali, Z.** Ottawa HR; Ottawa Business Journal. Suffering in silence; Turning a blind eye to mental illness at work. April 18, 2005. p 5-7.

Public Lectures and Invited Addresses

Academic and Research Day Presentations - December 2, 2005

Resident Oral Presentations

Dr. Fahad Al-Dosary - A case of an asymptomatic clomipramine highly toxic level and review of the literature.

Dr. Christopher Eaton - NMDA-receptor agonists as adjunctive treatment in schizophrenia.

Dr. Kerry Galenzoski - Pervasive development disorder and XYY syndrome.

Dr. Gary Kay - Evaluation of a partial hospitalization program for adolescents with moderate to severe psychiatric disorders: Effectiveness and predictors of treatment outcomes.

Dr. Chris Rae - Unmasking Kabuki Syndrome in a boy with ADHD and ODD.

Dr. Beata Wiatrowska - Are senior psychiatric residents prepared to provide care in a multicultural society?

Clinical Oral Presentations

Dr. Lisheng Du - Abnormal expression of serotonin receptors and BDNF in postmortem brain of suicide victims.

Ms. Veronica Felizardo - Secure Treatment Unit: The challenges of treatment and discharge planning with mentally disordered offenders in a hospital/jail.

Dr. Katherine Gillis - Needs and attitudes of family physicians and family medicine residents concerning the provision of collaborative mental health care.

Dr. Nancy Brookes - Evaluation of the Tidal Model of recovery and reclamation.

Ms. Lisa Murata - Preparing patients for electroconvulsive therapy (ECT): A pilot project.

Ms. Janna Willison - Dilemmas and limitations in detecting dementia in individuals with developmental disabilities.

Research Oral Presentations

Dr. Jean-Claude Bisserbe - Role of a functional 5-HT_{1A} receptor gene polymorphism as a risk factor for depression.

Dr. M.J. Dealberto - Why are immigrants more at risk for psychosis?

Dr. Paul Fedoroff - Risk assessment in men with intellectual disability.

Public Lectures and Invited Addresses

Academic Presentation

Dr. Richard Brown - Heritage of Donald Hebb to psychiatrists.

Poster Presentations

Serum testosterone and impulsive aggression in patients with dysfunctional anger.

Ahmed, A.G., Fedoroff, P., Korovessis, A., Curry, S., Stewart, W.

Dysfunctional anger and DSM-IV diagnoses.

Ahmed, A.G., Fedoroff, P., Korovessis, A., Curry, S., Stewart, W.

Practicing research-based, person-centered nursing in long term care with the Tidal Model®.

Barnett, S., Brookes, N., Murata, L.

Brief intervention as behavioral assessment.

Bialik, R., Corace, K., Dalton, C., Kroitor, Y.

Antidepressant drug combination from treatment initiation to improve therapeutic response in major depression.

Blier, P., Tremblay, P., Bergeron, R., Ward, H., Laberge, L., Hébert, C.

Biological and psychosocial correlates of childhood anxiety disorders.

Byrne, A., Koszycki, D., Furino, C., Faregh, N., Nguyen, H., Flament, M.

Nursing Students' experience of their psychiatric and mental health clinical placement.

Craig, Y., Brookes, N., Sharif, F.

Comparison of VRAG/SORAG items in a sample of developmentally delayed sex offenders and non-delayed sex offenders.

Curry, S., Fedoroff, P., Madrigano, G., Cunningham, C. Bradford, J.

Validation of risk assessment tools for individuals with problematic sexual behaviour and developmental delay: Preliminary results.

Curry, S., Fedoroff, P., Madrigano, G., Cunningham, C., Korovessis, S., Richards, D., Bradford, J., Griffiths, D.

A preliminary investigation of group emotion-focused therapy and skill building in depressed patients.

Dalton, C., Bialik, R., Murata, L.

Sleep state misperception in a psychiatric hospital outpatients sleep clinic.

Douglass, A., Orr, L., Busby, K., Vadneau, A., Fathi, K.

Risperidone reverses the escitalopram-induced inhibition of locus coeruleus norepinephrine neuron firing: A 5-HT_{2A} receptor mediated effect.

Dremencov, E., El Mansari, M., Blier, P.

Public Lectures and Invited Addresses

Examining the validity of a pre-assessment information collection tool for persons with a dual diagnosis.

Farrell, S., King-Andrews, H.

Measuring change in second and third year medical student attitudes towards mental illness.

Freeland, A., Gray, C., Stavrakaki, C., Braidek, C. Cloutier, P.

Needs and attitudes of family physicians and family medicine residents concerning the provision of collaborative mental health care.

Gillis, K., MacPhee, C., Swenson, R., Busing, N., Aubry, T. Clinch, J.

Regulation of the D3 dopaminergic receptor phosphorylation by adenylyl cyclases.

Gorji, H.

Caregiver expectations of emergency consultations for mental health concerns.

Gray, C. Cloutier, P., Kennedy, A., Smith, P., Laroche, L., Dumel, M., Hughes, R., Binder, K., Allevato, A., Segal, S., Stinson, S.

Effects of sustained administration of escitalopram on the 5-HT system in heterozygous mice for the 5-HT transporter.

Guiard, B., El Mansari, M., Blier, P.

Concurrent disorders group.

Hilton, C., Carrière, A.

Threat-relevant stimuli in obsessive-compulsive (OC) checkers: Attention profile study of sub-clinical OC checkers.

Irak, M., Flament, M.

Development of a typology of recommendations posed by a multi-disciplinary consultation outreach team with the Royal Ottawa Health Care Group (ROHCG) for clients with a dual diagnosis.

King-Andrews, H., Farrell, S.

The Brockville Risk Checklist: A one-year follow-up.

Laprade, K., Ahmed, A.G.

The Psychiatric Outreach Team.

Lusk-Ludwig, J., Rapoch, D., Colton, K., Farrell, S.

Sigma-1 receptor modulates N-methyl-D-aspartate receptor synaptic transmission and plasticity via SK channels.

Martina, M., Turcotte, M.E.B., Halman, S., Bergeron, R.

A meta-analysis of antidepressants, neuroleptics and mood stabilizers for borderline personality disorder: Effectiveness for anger symptoms.

Mercer, D., Douglass, A., Links, P.

Public Lectures and Invited Addresses

Prospective assessment of cannabis withdrawal in adolescents: A pilot study.
Milin, R., Manion, I., Dare, G.J.

Are psychiatrists using dangerous criteria to issue community treatment orders?
O'Brien, A-M., Farrell, S., Freeland, A.

Examining a biopsychosocial model of the development of body image, eating behaviours and weight control in adolescence.
Obeid, N., Faregh, N.

Admission trends study.
Petit, L.

Using navigation to investigate episodic memory impairment in patients with schizophrenia.
Phillips, J., Boulay, L., Mores, C., Denis, M., Boyer, P.

Assessing the key knowledge gaps identified by community service providers in their work with people with schizophrenia.
Poole, K.

Subjective well-being and community integration among clients of assertive community treatment.
Prince, P., Gerber, G.J.

Hope, spiritual well-being, and mental health.
Raab, K. A.

Desensitization of dopamine D1 receptor by G protein-coupled receptor kinases: Evidence for a receptor phosphorylation-independent process.
Sedaghat, K., Tiberi, M.

The effect of group psychotherapy on the life quality of patients with major depressive disorder referring to hospitals affiliated to Shiraz University of Medical Sciences.
Sharif, F., Noorian, K.

A systematic review of cardiovascular adverse events in SSRI antidepressant trials involving high risk patients.
Swenson, R., Doucette, S., Fergusson, D.

Building a healthy nursing practice environment and enhancing nursing practice.
Tansey, M., Brookes, N., Caldwell, C.

Effects of medication and cognitive behavior therapy, alone and in combination, on pathological gambling.
Telner, J., Ravindran, A., Bhatla, R., Cameron, C., Horn, E., Horne, D., Cebulski, L., Davies, A., Kelly, O.

August 29, 2006

Public Lectures and Invited Addresses

Evaluation of the youth partial hospitalization program for adolescents with moderate to severe psychiatric disorders.

Thatte, S., Woods, V., Westmacott, R., Nguyen, H., Makinen, J., Kay, G., Flament, M.

Evaluation in the Youth Psychiatry Program: Preliminary results.

Varshney, N., Milin, R., Walker, S., Makinen, J., Thatte, S.

IMHR Education Events: 2005

First Friday Lectures

February 4, 2005

"Fear-potentiated startle: A translational tool for research on fear and anxiety"

Speaker: Christian Grillon, Ph.D.

Chief, Unit of Affective Psychophysiology, Mood & Anxiety Disorders Program
National Institute of Mental Health, Bethesda, Maryland, U.S.A.

March 4, 2005

"Evidence for Prophylactic Efficacy of Antidepressants"

Speaker: Jean-Claude Bissebe, M.D., FRCPC

Clinical Director, Mood Disorder Program, ROH
Professor of Psychiatry, uOttawa

June 3, 2005

"Serotonin and Human Social Behaviour"

Speaker: Simon N. Young, Ph.D.

Professor, Department of Psychiatry, McGill University

September 26, 2005

"Marijuana research in animals: How far can we go to treat marijuana addiction and to treat mental disorders with marijuana?"

Speaker: Xia Zhang, M.D., Ph.D.

Associate Professor, Neuropsychiatry Research Unit
University of Saskatchewan, Saskatoon

October 7, 2005

"The Role of the Prefrontal Cortex in Bipolar Disorder: Evidence from the Maudsley Bipolar Project"

Speaker: Sophia Frangou, M.D., Ph.D.

Head, Section of Neurobiology of Psychosis
Sub-Dean, Institute of Psychiatry, De Crespigny Park, London, England

IMHR Education Events: 2005

Public Lecture Speaker's Tour 2005

May 6, 2005

Empowerment in Mental Health

Speakers:

Dr. Daniel Fisher, Founder of the National Empowerment Centre in Washington, D.C. and Member of the Presidential Council on Mental Health

Mr. Andrew Soloman, Author of the Noonday Demon: An Atlas of Depression
2001 National Book Award for Nonfiction

Program Evaluation & Evaluation Research

Educational and consultation series
April 19th to December 13th, 2005 (17 sessions)

Main Speaker: Professor Bob Flynn, Centre for Research on Community Services at the University of Ottawa

The series introduced and provided consultation on the basic and more advanced concepts of program evaluation to practitioners, program managers, members of the Institute of Mental Health Research and other interested parties at the ROHCG.

Experimental Design and Statistical Analysis

Two-Part Educational Workshop

Part 1: September 30th, 2005, Part 2: January and February, 2006

Main Speaker: Dr. Owen Kelly, Research Associate, uOttawa IMHR.

Part 1 of this workshop introduced participants to the widely used statistical program, SPSS, while Part 2 focused on the basics of inferential statistics and research methods. In this context, SPSS was used to answer specific research questions.

Interpersonal Psychotherapy for Depression

Two-Day Workshop (Organized in Collaboration with the Department of Psychiatry, University of Ottawa)

November 4-5, 2005

Workshop Facilitator: Dr. John Markowitz, Cornell University, New York.

This two-day workshop, organized by **Dr. D. Koszycki**, was designed for fully trained psychotherapists in the community to learn the principles, strategies and therapeutic techniques of interpersonal psychotherapy, an evidence-based treatment for depression. The purpose of this workshop was to translate research knowledge about an effective depression-focused psychotherapy into improved clinical practice. The workshop was attended by participants from across Canada.

IMHR Education Events: 2005

Clinical Research Training

Training Workshop for The Structured Clinical Interview for DSM-IV-TR
December, 2005; January 2006

Main Speakers: **Dr. Jean-Claude Bisserbe**, Clinical Director, Mood Disorders Program; **Dr. Diana Koszycki**, Research Unit Director, Stress and Anxiety Clinical Research Unit; **Dr. Patrice Boyer**, Research Unit Director, Schizophrenia Research Unit.

These training workshops covered in-depth the DSM-IV classification system and diagnostic criteria with an emphasis on mood, anxiety, schizophrenia and substance abuse, as well as provided an overview of the purpose, structure and principles of use for the SCID, and the psychometric properties for the different modules. To augment the interactive component of these sessions, didactic training and some role-playing for the various modules was included.

Appendix 1 Scientific Advisory Board

Dr. Anthony Phillips

Professor, Department of Psychiatry at the University of British Columbia

Dr. Phillips is widely recognized as one of Canada's pre-eminent neuroscientists in the area of mental health and addictions research. A psychopharmacologist by training, Dr. Phillips holds an appointment in the Department of Psychiatry, Faculty of Medicine at the University of British Columbia. He is Chairman of the Board of the CIHR Institute of Neuroscience, Mental Health and Addictions. In addition to a lifelong interest in brain research, Dr. Phillips has had a longstanding association with the development of biotechnology in Canada.

Dr. Rémi Quirion

Professor and Scientific Director at the Douglas Hospital Research Centre (a McGill affiliated teaching hospital) in Montreal, Quebec

Dr. Quirion has received the First Annual Award of National Mental Health Champion (Research) in addition to the titles of the Royal Society of Canada Fellow and the Chevalier de l'Ordre national du Québec. Under his leadership, the Douglas Hospital Research Centre has become a premier research facility in Canada in the fields of neurosciences and mental health. Dr. Quirion has promoted the development of clinical research in Neurology and Psychiatry as well as social and evaluation aspects of research in mental health and addiction.

Dr. Mark Bisby

Vice-President, Research for the Canadian Institutes of Health Research (CIHR)

Dr. Bisby holds a D. Phil. from Oxford University and is a past-President of the Canadian Federation of Biological Societies and the Canadian Physiological Society. A professor, researcher and former Assistant Dean of Medical Sciences at the University of Calgary, Dr. Bisby was Head of the Department of Physiology at Queen's University before moving to MRC. He has published over 100 scientific articles in the area of neuroscience, most recently the inappropriate regenerative events that follow nerve injury which lead to chronic pain.

Appendix 1 Scientific Advisory Board

Dr. Glen Baker

Professor and Vice-Chair, Department of Psychiatry at the University of Alberta

Much of Dr. Baker's research has dealt with the metabolism and mechanisms of action of drugs used to treat psychiatric disorders, particularly depression, anxiety disorders and schizophrenia. He has also been involved extensively in the development of novel techniques for analysis of biogenic amines, amino acids, drugs and their metabolites. The research on antidepressants, amino acids and drug metabolism has resulted in the recent development of novel drugs which appear to be neuroprotective and have potential for treatment of stroke.

Dr. Hymie Anisman

Professor in the Institute of Neurosciences at Carleton University

Dr. Hymie Anisman is a world-renowned neuroscientist and leading researcher on the causes of stress-induced illness. His research involves the exploration of the pharmacological and neurochemical basis for depression and anxiety for which he has received numerous international citations. He and his team are now engaged in extending that research beyond looking for causes to looking for ways to counteract the changes brought on by stress. Dr. Anisman also holds a prestigious Canadian Research Chair in the Neurosciences.

Dr. Howard Alper

Professor and Vice Rector of Research at the University of Ottawa

Dr. Alper is a renowned chemist and a world leader in the field of catalytic organic chemistry. Last year, he was appointed president of the Royal Society of Canada. Dr. Alper is the first winner of the prestigious Gerhard Herzberg Canada Gold Medal for Science and Engineering. Dr. Alper has also been given one of the highest honours awarded by the French Government, an appointment as an Officer of the National Order of Merita.